Indian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy’s and Cipla saw significant drops in their net profits and operating margins. However, their domestic businesses continued to perform well, offering a positive outlook. Obesity therapies and specialty product launches are expected to drive future growth for these companies. Analysts have consequently reduced earnings forecasts for the upcoming fiscal years.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.